

From: [michael kaplan](#)
To: [Clark, Jacob, DOH](#)
Subject: [EXTERNAL] Public comment on proposed 7.35.3 NMAC, October 2, 2026 hearing.
Date: Thursday, October 1, 2026 4:48:37 AM

You don't often get email from mkspine@me.com. [Learn why this is important](#)

CAUTION: This email originated outside of our organization. Exercise caution prior to clicking on links or opening attachments.

To the New Mexico Department of Health:

I am a New Mexico resident in Santa Fe, and I am also a clinician. I am writing to comment on proposed rule 7.35.3 NMAC ahead of the October 2, 2026 hearing.

Legal psilocybin-assisted therapy helped me profoundly change my life, my outlook, and my circumstances. Through the experience, I was able to better regulate myself, find the strength to stand up for myself, and begin making meaningful changes in an abusive relationship. It also gave me an immediate sense of hope during a period of severe anxiety and depression, when I had begun considering other, potentially harmful substances as a way of coping.

I ask the Department to make the following changes in the final rule.

1. The property-owner statement, 7.35.3.11(B)(9).

Delete paragraph (B)(9) of 7.35.3.11.

The landlord interest that justifies the cannabis provision, smoking on the property, is not present in a supervised psilocybin session administered by a licensed facilitator. A signed acknowledgment gives an owner nothing to gain and something to lose, so many will decline to sign, and care at home for anyone who does not own their home will end before they are able to receive treatment.

2. The certifying clinician, 7.35.3.8 and 7.35.3.9(D).

Remove the certifying clinician design. In its place, regulate around the specific contraindications, medical histories and medications that warrant clinical review. Where a risk factor is identified, require an attestation from a clinician whose scope of practice fits that risk that screening was conducted and benefits outweigh risks.

The design exceeds the Act and misunderstands where the risk is. The most significant risks in psilocybin-assisted therapy are psychological, or medical risks that must be screened on the day of administration, such as intoxication. A one-time “prescriber” gateway misses them. It also creates a clinical encounter whose only purpose is program entry, which insurers will treat as lacking independent medical necessity, inviting claim denials and clawbacks.

3. The patient application, 7.35.3.8.

Strike the patient application process.

It has no legal or policy justification in a supervised-use program. It adds administrative burden for the department, lengthens the wait for care, creates another store of patient data that can be accessed without consent or unlawfully taken, and further stigmatizes patients.

Thank you for considering my comments.

Michael Kaplan, MD

Santa Fe, New Mexico